OBJECTIVE: To characterise prevalence of traditional cardiovascular disease (CVD) risk factors, assess CVD risk and examine the effect of simulated interventions on CVD risk among HIV-infected Asian Indians. METHODS: Cross-sectional data between September 2015 and July 2016 wer used to describe the prevalence of CVD risk factors. Five risk scores (Framingham, Data Collection on Adverse Effects of Anti-HIV Drugs Study (D:A:D), Atherosclerotic Cardiovascular, QRISK2 and Ramathibodi-Electricity Generating Authority of Thailand were used to estimate CVD risk. The effect of seven sensitivity analyses: smoking prevention; diabetes prevention; optimal blood pressure and dyslipidaemia control (total cholesterol, high-density lipoprotein (HDL)); CD4 augmentation and a combination of the scenarios on the median cumulative D:A:D CVD scores were assessed. RESULTS: Of 402 enrolled, 56% were women, median age was 40 years (IQR: 35-45 years) and median time-updated CD4 counts were 378 cells/μL (IQR: 246-622). Fifty-five and 28% had ever been screened for hypertension and diabetes, respectively prior to enrolment. The prevalence of diabetes, hypertension, hypercholesterolaemia, low HDL, previous and current smokers were 9%, 22%, 20%, 39%, 14% and 4%, respectively. Thirty-six per cent had intermediate-to-high 5-year CVD risk by D:A:D estimates. Thirty-two per cent were eligible for statin therapy by American College of Cardiology/American Heart Association guidelines; 2% were currently on statins. In sensitivity analyses, diabetes prevention was associated with the highest reduction of CVD risk. CONCLUSION: CVD at younger ages among Asian Indian people living with HIV appear to be an imminent risk for morbidity. Stepping up of preventive services including screening services and prescription of statins are important strategies that must be considered.
OBJECTIVE: To characterise prevalence of traditional cardiovascular disease (CVD) risk factors, assess CVD risk and examine the effect of simulated interventions on CVD risk among HIV-infected Asian Indians. METHODS: Cross-sectional data between September 2015 and July 2016 wer used to describe the prevalence of CVD risk factors. Five risk scores (Framingham, Data Collection on Adverse Effects of Anti-HIV Drugs Study (D:A:D), Atherosclerotic Cardiovascular, QRISK2 and Ramathibodi-Electricity Generating Authority of Thailand were used to estimate CVD risk. The effect of seven sensitivity analyses: smoking prevention; diabetes prevention; optimal blood pressure and dyslipidaemia control (total cholesterol, high-density lipoprotein (HDL)); CD4 augmentation and a combination of the scenarios on the median cumulative D:A:D CVD scores were assessed. RESULTS: Of 402 enrolled, 56% were women, median age was 40 years (IQR: 35-45 years) and median time-updated CD4 counts were 378 cells/μL (IQR: 246-622). Fifty-five and 28% had ever been screened for hypertension and diabetes, respectively prior to enrolment. The prevalence of diabetes, hypertension, hypercholesterolaemia, low HDL, previous and current smokers were 9%, 22%, 20%, 39%, 14% and 4%, respectively. Thirty-six per cent had intermediate-to-high 5-year CVD risk by D:A:D estimates. Thirty-two per cent were eligible for statin therapy by American College of Cardiology/American Heart Association guidelines; 2% were currently on statins. In sensitivity analyses, diabetes prevention was associated with the highest reduction of CVD risk. CONCLUSION: CVD at younger ages among Asian Indian people living with HIV appear to be an imminent risk for morbidity. Stepping up of preventive services including screening services and prescription of statins are important strategies that must be considered.
Authors: R M Anjana; R Pradeepa; M Deepa; M Datta; V Sudha; R Unnikrishnan; A Bhansali; S R Joshi; P P Joshi; C S Yajnik; V K Dhandhania; L M Nath; A K Das; P V Rao; S V Madhu; D K Shukla; T Kaur; M Priya; E Nirmal; S J Parvathi; S Subhashini; R Subashini; M K Ali; V Mohan Journal: Diabetologia Date: 2011-09-30 Impact factor: 10.122
Authors: Wendy S Post; Matthew Budoff; Lawrence Kingsley; Frank J Palella; Mallory D Witt; Xiuhong Li; Richard T George; Todd T Brown; Lisa P Jacobson Journal: Ann Intern Med Date: 2014-04-01 Impact factor: 25.391
Authors: Anne-Lise Paisible; Chung-Chou H Chang; Kaku A So-Armah; Adeel A Butt; David A Leaf; Matthew Budoff; David Rimland; Roger Bedimo; Matthew B Goetz; Maria C Rodriguez-Barradas; Heidi M Crane; Cynthia L Gibert; Sheldon T Brown; Hilary A Tindle; Alberta L Warner; Charles Alcorn; Melissa Skanderson; Amy C Justice; Matthew S Freiberg Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: A Mocroft; R Brettle; O Kirk; A Blaxhult; J M Parkin; F Antunes; P Francioli; A D'Arminio Monforte; Z Fox; J D Lundgren Journal: AIDS Date: 2002-08-16 Impact factor: 4.177
Authors: Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice Journal: JAMA Intern Med Date: 2013-04-22 Impact factor: 21.873
Authors: Hossein Bahrami; Matthew Budoff; Sabina A Haberlen; Pantea Rezaeian; Kerunne Ketlogetswe; Russell Tracy; Frank Palella; Mallory D Witt; Michael V McConnell; Lawrence Kingsley; Wendy S Post Journal: J Am Heart Assoc Date: 2016-06-27 Impact factor: 5.501
Authors: Christopher J Miller; Jason V Baker; Alison M Bormann; Kristine M Erlandson; Katherine Huppler Hullsiek; Amy C Justice; Jacqueline Neuhaus; Roger Paredes; Kathy Petoumenos; Deborah Wentworth; Alan Winston; Julian Wolfson; James D Neaton Journal: PLoS One Date: 2014-04-11 Impact factor: 3.240
Authors: Rimke Bijker; Nagalingeswaran Kumarasamy; Sasisopin Kiertiburanakul; Sanjay Pujari; Wilson Lam; Romanee Chaiwarith; Wing W Wong; Adeeba Kamarulzaman; Pacharee Kantipong; Anchalee Avihingsanon; Kinh V Nguyen; Junko Tanuma; Oon Tek Ng; Benedict Lh Sim; Tuti P Merati; Jun Y Choi; Rossana Ditangco; Evy Yunihastuti; Ly P Sun; Cuong D Do; Jeremy Ross; Matthew Law Journal: Antivir Ther Date: 2019
Authors: Derek Larson; Seung Hyun Won; Anuradha Ganesan; Ryan C Maves; Karl Kronmann; Jason F Okulicz; Xiuping Chu; Christina Schofield; Thomas O'Bryan; Brian K Agan; Robert Deiss Journal: HIV Med Date: 2021-10-26 Impact factor: 3.180
Authors: Damariz Marín-Palma; Gustavo A Castro; Jaiberth A Cardona-Arias; Silvio Urcuqui-Inchima; Juan C Hernandez Journal: Front Immunol Date: 2018-06-14 Impact factor: 7.561